Ductal carcinoma in situ: Terminology, classification, and natural history

Journal of the National Cancer Institute - Monographs

Volumn , Issue 41, 2010, Pages 134-138

  Allred, D Craig ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST DUCT; BREAST EPITHELIUM; CANCER CLASSIFICATION; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CARCINOMA IN SITU; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; FEMALE; HISTORY; HUMAN; HYPERPLASIA; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; BREAST; BREAST TUMOR; CALCINOSIS; CLASSIFICATION; DISEASE COURSE; EPITHELIUM CELL; NECROSIS; NOMENCLATURE; PATHOLOGY; RADIOGRAPHY; REVIEW; ULTRASTRUCTURE;

BREAST; BREAST NEOPLASMS; CALCINOSIS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL DIFFERENTIATION; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; HUMANS; MAMMOGRAPHY; NECROSIS; TERMINOLOGY AS TOPIC;

EID: 79952198032     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgq035     Document Type: Article

References (49)

1. Osborne MP. Breast anatomy and development. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Harris JRLM, Morrow M, Hellman S, Osborne CK, trans. Diseases of the Breast. 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2004:3-14.
2. Allred DC. Biological characteristics of ductal carcinoma in situ. In: Silverstein ML, ed. Ductal Carcinoma In Situ of the Breast. 2nd ed. Philadelphia, PA: Lipincott, Williams and Wilkins; 2002:37-48.
3. Wellings RR, Jensen HM. On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst. 1973;50(5):1111-1118.
4. Allred DC. Biological features of human premalignant breast disease and the progression to cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2009:323-334.
5. Cheatle GL, Cutler M. Malignant epithelial neoplasia. Carcinoma. The precancerous or potentially carcinomatous state. In: Cheatle GL, Cutler M, eds. Tumours of the Breast. 1st ed. Philadelphia, PA: Lippincott; 1926:161-332.
6. Foote FW, Stewart FW. Comparative studies of cancerous versus noncancerous breasts. Ann Surg. 1945;121(1):6-53, 197-222.
7. Page DL, Rogers LW. Carcinoma in situ (CIS). In: Page DL, Anderson TJ, eds. Diagnostic Histopathology of the Breast. 1st ed. New York, NY: Churchill Livingston; 1987:157-174.
8. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 1975;55(2):231-273.
9. Muir R. The evolution of carcinoma of the mamma. J Pathol Bacteriol. 1941;LII(2):155-172.
10. Fechner RE. History of ductal carcinoma in situ. In: Silverstein ML, ed. Ductal Carcinoma In Situ of the Breast. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2002:3-16.
11. Morrow M, Harris JR. Ductal carcinoma in situ and microinvasive carcinoma. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004:521-537.
12. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001;8(1):47-61.
13. Dalgin GS, Alexe G, Scanfeld D, et al. Portraits of breast cancer progression. BMC Bioinformatics. 2007;8:291.
14. Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135-144.
15. Kuerer HM, Albarracin CT, Yang WT, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009;27(2):279-288.
16. Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007;117(11):3155-3163.
17. Schnitt SJ, Silen W, Sadowsky NL, Connolly JL, Harris JR. Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med. 1988;318(14):898-903.
18. Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. Natl Cancer Inst Monogr. 1997;22:151-156.
19. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340(19):1455-1461.
20. Solin LJ, Kurtz J, Forquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996;14(3):754-763.
21. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 2008;14(2):370-378.
22. Shoker BS, Sloane JP. DCIS grading schemes and clinical implications. Histopathology. 1999;35(5):393-400.
23. Tavassoli FA, Schitt SJ, Hoefler H, et al. Intraductal proliferative lesions. In: Tavassoli FA, Devillee P, eds. Pathology & Genetics. Tumours of the Breast and Female Genital Organs.Lyon, France: IARC Press; 2003:63-73.
24. Elston EW, Ellis IO. Method for grading breast cancer. J Clin Pathol. 1993;46(2):189-190.
25. Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153-3158.
26. Bernstein L. The epidemiology of breast carcinoma in situ. In: Silverstein ML, eds. Ductal Carcinoma In Situ of the Breast. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2002:22-34.
27. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146-151.
28. Page DL. Cancer risk assessment in benign breast biopsies. Human Pathol. 1986;17(9):871-874.
29. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103(12):2481-2484.
30. O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC. Loss-of-heterozygosity analysis in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998;(90):697-703.
31. Allred DC, Medina D. The relevance of mouse models to the development and progression of human breast cancer. J Mammary Gland Biol Neoplasia. 2008;(13):279-288.
32. Miller FR. Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia. 2000;5(4):379-391.
33. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR. The classification of ductal carcinoma in situ and its association with biological markers. Semin Diag Pathol. 1994;11(3):199-207.
34. Gupta SK, Douglas-Jones AG, Morgan JM, Mansel RE. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer. 1997;80(9):1740-1745.
35. Moreno A, Lloveras B, Figueras A, et al. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. Mod Pathol. 1997;10(11):1088-1092.
36. Poller DN, Silverstein MJ, Galea M, et al. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol. 1994;7(2):257-262.
37. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(10):5974-5979.
38. Porter D, Lahti-Domenici J, Keshaviah A, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;1(5):362-375.
39. Castro NP, Osorio CA, Torres C, et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res. 2008;10(5):R87.
40. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res. 2006;8(5):R61.
41. Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6(1):17-32.
42. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392-401.
43. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today. 2000;6(8):324-329.
44. Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia. 2005;10(3):231-247.
45. Bestill WL Jr, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma: long-term follow-up after treatment by biopsy alone. JAMA. 1978;239(18):1863-1867.
46. Eusebi V, Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. Sem Diag Pathol. 1994;11:223-235.
47. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer. 1982;49(4):751-758.
48. Rosen PP, Braun DW Jr, Kinne DE. The clinical significance of preinvasive breast carcinomas. Cancer. 1980;46:919-925.
49. O'Sullivan MJ, Morrow M. Ductal carcinoma in situ-current management. Surg Clin North Am. 2007;87(2):333-351, viii.